All In Biotech

Drug Trial Radar · NCT07286149

A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

KEYMAKER-U01 Substudy 01F: A Phase 1b/2 Umbrella Study With Rolling Arms of Investigational Agents for Previously Treated Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations

Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Apr 30, 2026

Primary completion

Aug 17, 2029

Study completion Apr 13, 2032

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
Daiichi Sankyo
First posted
Dec 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers want to learn if MK-1084, the study medicine, can treat advanced or metastatic non-squamous NSCLC. MK-1084 is a targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread. The goals of this study are to learn: * About the safety of MK-1084 and if people tolerate it when taken with other treatments * How many people have the cancer respond (get smaller or go away) to the treatments

Conditions

  • Lung Neoplasm Malignant

Interventions

  • MK-1084Drug

    Oral administration

  • Patritumab deruxtecanBiological

    IV infusion

  • Sacituzumab tirumotecanBiological

    IV Infusion

  • CetuximabBiological

    IV Infusion

  • Rescue MedicationsDrug

    Participants receive rescue medication at the investigator's discretion for prevention of nausea and vomiting, per approved product label. Recommended rescue medications are histamine-1 (H1) receptor antagonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion, or steroid mouthwash (dexamethasone or equivalent), 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist, neurokinin 1 (NK-1) receptor antagonist and corticosteroid.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experience a Dose Limiting Toxicity (DLT)Time frame: Up to 42 days
  2. Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 63 months
  3. Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 62 months
  4. Objective Response Rate (ORR)Time frame: Up to approximately 63 months

Locations

29 sites in 11 countries. Site status is shown where the registry gives one.

  • Clermont Oncology Center ( Site 0041)

    Clermont, Florida · Recruiting

  • University of Illinois Hospital & Health Sciences System ( Site 0044)

    Chicago, Illinois · Recruiting

  • Providence Portland Medical Center ( Site 0043)

    Portland, Oregon · Recruiting

  • Providence Oncology and Hematology Care Clinic - Westside ( Site 0059)

    Portland, Oregon · Recruiting

  • Hospital São Lucas da PUCRS ( Site 0283)

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0282)

    Barretos, São Paulo, Brazil · Recruiting

  • Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0286)

    São José do Rio Preto, São Paulo, Brazil · Recruiting

  • Hospital Paulistano ( Site 0280)

    São Paulo, São Paulo, Brazil · Recruiting

  • Centro de Estudios Clínicos SAGA-CECSAGA ( Site 0162)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Fundación Arturo López Pérez ( Site 0161)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Bradfordhill ( Site 0160)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Guangdong Provincial People s Hospital ( Site 0300)

    Guangzhou, Guangdong, China · Recruiting

  • Yunnan Province Cancer Hospital ( Site 0302)

    Kunming, Yunnan, China · Recruiting

  • UniversitaetsklInikum Tuebingen ( Site 0192)

    Tübingen, Baden-Wurttemberg, Germany · Recruiting

  • THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA" ( Site 0204)

    Athens, Attica, Greece · Recruiting

  • Alexandra General Hospital of Athens-ONCOLOGY DEPT. ( Site 0205)

    Athens, Attica, Greece · Recruiting

  • Papageorgiou General Hospital of Thessaloniki ( Site 0206)

    N.Efkarpia, Thessaloniki, Greece · Recruiting

  • Queen Mary Hospital ( Site 0230)

    Hong Kong, Hong Kong · Recruiting

  • Hong Kong United Oncology Centre ( Site 0232)

    Jordan, Hong Kong · Recruiting

  • Prince of Wales Hospital ( Site 0231)

    Shatin, Hong Kong · Recruiting

  • Shaare Zedek Medical Center ( Site 0186)

    Jerusalem, Israel · Recruiting

  • Meir Medical Center ( Site 0181)

    Kfar Saba, Israel · Recruiting

  • Sheba Medical Center ( Site 0180)

    Ramat Gan, Israel · Recruiting

  • IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" ( Site 0176)

    Meldola, Forli-Cesena, Italy · Recruiting

  • Severance Hospital, Yonsei University Health System ( Site 0080)

    Seoul, South Korea · Recruiting

  • Hospital Clinic de Barcelona ( Site 0092)

    Barcelona, Spain · Recruiting

  • Hospital Universitario Virgen Macarena ( Site 0093)

    Seville, Spain · Recruiting

  • Institut Català d'Oncologia - L'Hospitalet ( Site 0090)

    Hospitalet, Barcelona, Spain · Recruiting

  • HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 0091)

    Pozuelo de Alarcón, Madrid, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.